Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2024-04-02 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
2023年度董事会财务与审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度董事会财务与审计委员会履职情况报告" which translates to "2023 Annual Report on the Performance of the Board's Financial and Audit Committee." It details the activities, meetings, and evaluations conducted by the financial and audit committee of the board during the year 2023. The content includes oversight of financial reports, audit work, internal controls, and governance related to financial and audit matters. It is a report on the committee's duties and performance rather than a full annual report or audit report itself. The document length is 3063 characters, which is relatively short but contains substantive content about the committee's work, not just an announcement or certification. This type of document fits best under Audit Report / Information (AR) as it focuses on audit committee activities, audit oversight, and related financial governance matters, distinct from the full Annual Report (10-K) or a simple announcement (RPA). FY 2023
2024-04-02 Chinese
第四届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of various reports and proposals including the 2023 Supervisory Board Work Report, 2023 Annual Report and summary, 2023 Financial Final Report, 2024 Financial Budget Report, 2023 Equity Distribution Plan, special audit reports, fundraising usage report, accounting policy changes, and supervisory remuneration plan. The document repeatedly states that these reports will be submitted to the shareholders' meeting for approval and are disclosed on the Beijing Stock Exchange information platform. The document itself does not contain the full annual report or financial statements but is a formal announcement of the Supervisory Board's meeting resolutions. The document length is 2854 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full annual report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and related disclosures, not the full annual report or financial statements themselves.
2024-04-02 Chinese
董事会关于独立董事独立性自查情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It references relevant laws and regulations about independent directors and concludes on their independence status. The document is short (1002 characters) and focuses on governance and compliance matters related to board members' independence. It is not a financial report, earnings release, or announcement of voting results. It fits best under Board/Management Information (MANG) as it relates to board member status and governance compliance.
2024-04-02 Chinese
关于使用自有闲置资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes specifics about the amounts, types, expected yields, and terms of various short-term, low-risk financial products purchased by the company. The document also references prior board and shareholder approvals, internal control measures, risk warnings, and detailed tables of ongoing and matured entrusted financial products. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about the company's capital management activities, specifically the use of idle funds for investment in financial products. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is substantial (9225 characters), and it contains detailed substantive information, not just an announcement of a report or a certification. Therefore, the appropriate classification is CAP with high confidence.
2024-04-02 Chinese
2023年度独立董事述职报告（黄元林）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's attendance at board and shareholder meetings, participation in committees, independent opinions, special powers exercised, communication with audit institutions, on-site work, and protection of minority shareholders' rights. The content focuses on the independent director's duties, oversight, and governance activities during the year 2023. It does not contain financial statements or audit results but is a detailed report on board/management activities and governance oversight. This fits best under Board/Management Information (MANG) as it relates to the activities and responsibilities of a board member rather than a full annual report, audit report, or governance policy document. The document length is 4587 characters, which is sufficient for a detailed report but not a full financial report. Therefore, the classification is MANG with high confidence.
2024-04-02 Chinese
2023年年度权益分派预案暨落实“提质守信重回报”行动公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a 2023 annual equity distribution plan and announcement of implementing a "quality, trust, and return" action. It discusses the audited 2023 financial report, the proposed cash dividend distribution plan based on undistributed profits, and the company's dividend policy as per its articles of association. It also mentions the board and supervisory committee approvals and that the plan is subject to shareholder meeting approval. The document is an announcement of a dividend distribution plan and related corporate governance matters, not the actual annual report or financial statements. It is not a full annual report (10-K) or earnings release (ER), but a notice about dividend amount and distribution plan. Therefore, it fits best under the category of Notice of Dividend Amount (DIV). The document length is 2118 characters, which is consistent with an announcement rather than a full report.
2024-04-02 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.